Allied Corp.

  • ISIN: US0191141078
  • Land: .

Nachricht vom 23.09.2019 | 12:03

Allied Corp. Files First US Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder

DGAP-News: Allied Corp. / Key word(s): Miscellaneous

23.09.2019 / 12:03
The issuer is solely responsible for the content of this announcement.


Kelowna, British Columbia--(Newsfile Corp. - September 23, 2019) - Allied Corp. ("Allied") (OTC PINK: ALID) - an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today's medical issues - is pleased to announce the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).

This marks the first of a series of proposed filings, along with recent trademark filings, as part of the Company's Intellectual Property and Pharma Development (IP&PD) Strategy. This Pharma Development Strategy includes serving those suffering from mental health issues, with a particular focus on those suffering from symptoms related to PTSD.

The products developed under the Company's IP&PD strategy are initially geared towards veterans and first responders and will further be available to anyone else suffering from symptoms related to PTSD. These products will be made available for sale under Allied's recently launched natural health hemp-derived retail product line, TACTICAL RELIEF™.

"We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world," said David Weinkauf, VP Pharma Development. "Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing."

Allied is dedicated to promoting a holistic approach to healing that reinforces a specialized model of care. The model's main goal is to assist in preventing suicides among veterans and first responders who are suffering from PTSD or other disorders related to mental health.

"Currently, there are approximately 8 million people in the United States alone who suffer from symptoms related to PTSD. Although there are certain cognitive therapies that have proven to be helpful, there is no pharmaceutical drug that has an indication for this disease target. PTSD is a disorder that not only affects the person suffering, but his/her family and community as well. Through this patent filing, we have now taken the first step in our pharma development plan, as well as, protected our medical formulation that is focused on this disease target." says Calum Hughes, CEO, Allied Corp.

For more information on Allied Corp., visit www.allied.health

About Allied Corp.

Allied Corp. is an international medical cannabis production company with a mission to address today's medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

Media Contact:
allied@5wpr.com

Investor Relations:
Anthony Zelen
ir@allied.health
+1-778-388-5258

Forward-Looking Statements:

This news release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate", "become", "objective", "may", "will", "might", "should", "could", "can", "intend", "expect", "believe", "estimate", "predict", "potential", "plan", "is designed to", "project", "continue", or similar expressions suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, that the Company will receive its US Patent for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD) and that the Company's proposed hemp-derived retail product line, TACTICAL RELIEF™, will be accepted by service members and first responders. We are also subject to various additional risks as described in our SEC filings at www.SEC.gov.

Forward-looking statements are based on management's current expectations and may materially differ from actual results. Further, such forward-looking statements are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48017

Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/48017
News Source: Newsfile


23.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

23. September 2020